您当前所在的位置:首页 > 产品中心 > 产品详细信息
985-12-6 分子结构
点击图片或这里关闭

(1Z)-1-[(3,4-diethoxyphenyl)methylidene]-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline

ChemBase编号:4472
分子式:C24H31NO4
平均质量:397.50724
单一同位素质量:397.22530848
SMILES和InChIs

SMILES:
O(c1cc2CCN/C(=C\c3cc(OCC)c(OCC)cc3)/c2cc1OCC)CC
Canonical SMILES:
CCOc1cc(ccc1OCC)/C=C/1\NCCc2c1cc(OCC)c(c2)OCC
InChI:
InChI=1S/C24H31NO4/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20/h9-10,13-16,25H,5-8,11-12H2,1-4H3/b20-13-
InChIKey:
OMFNSKIUKYOYRG-MOSHPQCFSA-N

引用这个纪录

CBID:4472 http://www.chembase.cn/molecule-4472.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
(1Z)-1-[(3,4-diethoxyphenyl)methylidene]-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline
IUPAC传统名
drotaverine
商标名
No-Spa
Drotin
别名
drotaverin
Drotaverine
(Z)-1-(3,4-diethoxybenzylidene)-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline
CAS号
985-12-6
PubChem SID
160967904
99443287
PubChem CID
1712095

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID 价格
InterBioScreen
BB_SC-4659 external link 加入购物车 请登录

理论计算性质

理论计算性质

JChem ALOGPS 2.1
质子受体 质子供体
LogD (pH = 5.5) 2.3096476  LogD (pH = 7.4) 3.892906 
Log P 4.191375  摩尔折射率 117.994 cm3
极化性 44.95594 Å3 极化表面积 48.95 Å2
可自由旋转的化学键 里宾斯基五规则 true 
Log P 5.35  LOG S -5.3 
溶解度 2.00e-03 g/l 

分子性质

分子性质

生物活性(PubChem)

详细说明

详细说明

DrugBank DrugBank
DrugBank -  DB06751 external link
Item Information
Drug Groups approved
Description Drotaverine (INN, also known as drotaverin) is an antispasmodic drug, structurally related to papaverine. Drotaverine is a selective inhibitor of phosphodiesterase 4, and has no anticholinergic effects. Drotaverine has been shown to possess dose-dependant analgesic effects in animal models. One small study has shown drotaverine to be eliminated mainly non-renally.
Indication Used in the treatment of functional bowel disorders and alleviating pain in renal colic.
Pharmacology Drotaverine is a spasmolytic agent by inhibiting PDE4 in smooth muscle cells.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic
Absorption Bioavailability is highly variable
Half Life 7 to 12 hours
Protein Binding 80 to 95%
References
Bolaji OO, Onyeji CO, Ogundaini AO, Olugbade TA, Ogunbona FA: Pharmacokinetics and bioavailability of drotaverine in humans. Eur J Drug Metab Pharmacokinet. 1996 Jul-Sep;21(3):217-21. [Pubmed]
External Links
Wikipedia

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Bolaji OO, Onyeji CO, Ogundaini AO, Olugbade TA, Ogunbona FA: Pharmacokinetics and bioavailability of drotaverine in humans. Eur J Drug Metab Pharmacokinet. 1996 Jul-Sep;21(3):217-21. Pubmed
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle